−1470KRW
−35.32 BKRW
24.75 M
About MEDPACTO
Sector
CEO
Seong-Jin Kim
Headquarters
Seoul
Website
Employees (FY)
63
Founded
2013
ISIN
KR7235980000
FIGI
BBG00QT4TP96
MedPacto, Inc. researches and develops anti-cancer drugs. It engages in the development of therapeutic products to cure ulcer or neuropathy caused by diabetes. The company was founded by Seong-Jin Kim on June 19, 2013 and is headquartered in Seoul, South Korea.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 235980 is 9270 KRW — it has decreased by 3.94% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange MEDPACTO stocks are traded under the ticker 235980.
235980 stock is 13.85% volatile and has beta coefficient of 1.86. Check out the list of the most volatile stocks — is MEDPACTO there?
Yes, you can track MEDPACTO financials in yearly and quarterly reports right on TradingView.
235980 stock has fallen by 12.79% compared to the previous week, the month change is a 38.41% fall, over the last year MEDPACTO has showed a 56.74% decrease.
235980 net income for the last quarter is −7.59 B KRW, while the quarter before that showed −6.20 B KRW of net income which accounts for −22.48% change. Track more MEDPACTO financial stats to get the full picture.
Today MEDPACTO has the market capitalization of 334.80 B, it has decreased by 6.26% over the last week.
No, 235980 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 235980 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDPACTO stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 63.00 employees. See our rating of the largest employees — is MEDPACTO on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDPACTO technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDPACTO stock shows the sell signal. See more of MEDPACTO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.